Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

201

3:10 Understanding Phenotypic Heterogeneity: Can We Get to Precision-Based Care in PARDS? J.R. Grunwell, MD, PhD, Atlanta, GA 3:25 PARDS in the Digital Era: Leveraging Informatics and Data Science N. Sanchez-Pinto, MD, MCI, Chicago, IL 3:40 Question and Answer R.G. Khemani, MD, MSCR, Los Angeles, CA

CLINICAL SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5 MOC Points Available: 1.5

B90

IMPROVING THE DIAGNOSIS AND MANAGEMENT OF PEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME

Assemblies on Critical Care; Pediatrics 2:15 PM - 3:45 PM

BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

Marriott Marquis Washington Marquis Ballroom Salon 6 (Level M2)

Target Audience Clinicians and researchers who care for patients with ARDS Objectives At the conclusion of this session, the participant will be able to: • improve the diagnosis of pediatric ARDS • integrate new guidelines for the management of PARDS into current practice • use informatics and data science techniques appropriately in the care of children with PARDS Acute Respiratory Distress Syndrome (ARDS) occurs in both children and adults, but the management and diagnosis of Pediatric Acute Respiratory Distress Syndrome (PARDS) must consider factors which are unique to children and pediatric ICU practice. In 2015, the Pediatric Acute Lung Injury Consensus Conference (PALICC) published a definition of PARDS, along with clinical practice guidelines. Since then, there has been a wealth of new research focused on PARDS, which has prompted an update to PALICC, termed PALICC-2. This session focuses on important concepts and themes from PALICC-2 which are crucial for the clinical care of children with PARDS. Chairing: R.G. Khemani, MD, MSCR, Los Angeles, CA Y. Lopez-Ferandez, MD, PhD, Bizkaia, Spain 2:15 Introduction and Overview of PALICC-2 G. Emeriaud, MD, PhD, Montreal, Canada 2:20 Patient Speaker C. Clark, Gainesville, FL 2:25 How Do We Account for Changing Practice with HFNC and NIV in Defining PARDS? S. Shein, MD, Cleveland, OH 2:40 Lung Protective Bundles and Monitoring in PARDS A. Bhalla, MD, MSc, Los Angeles, CA 2:55 What Are the Most Important Outcomes to Follow in PARDS Patients, and Can We Modulate Them with our Therapies? E. Killien, MD, Seattle, WA

B91 LUNG AGING: WHY YOUR FEV1 IS FALLING AND PNEUMONIA IS YOUR FINAL FRIEND Assemblies on Respiratory Cell and Molecular Biology; Respiratory Structure and Function 2:15 PM - 3:45 PM Walter E. Washington Convention Center Room 204 A-C (Level 2) Target Audience Clinicians, physiologists, molecular biologists, epidemiologists, and all points in between Objectives At the conclusion of this session, the participant will be able to: • describe new findings about the major pathophysiologic elements of the aging lung • apply the pathophysiology of lung aging to better manage the common clinical scenarios of ILD, COPD, Th1 asthma, lung carcinogenesis • improve the healthspan of individuals at risk for age-related lung disorders, including the consideration of “senolytic” prevention maneuvers We are all aging. Yet the machinery of aging is not well understood. Many disorders with which clinicians struggle are strongly age-associated (UIP/IPF, COPD, Th1 ASTHMA, Lung Cancer, others). Some central dysfunctions of aging include stochastic deterioration of biologic programs; senescence programming, oxidative damage, telomeric maintenance failure, immunologic exhaustion, and other processes. This symposium will review some of the known processes of aging as they relate to the lung, review some of the most salient studies, and reach for a unified theme for normal as well as accelerated lung aging that may be

addressable with preventatives and therapeutics. Chairing: S.D. Spivack, MD, MPH, Bronx, NY

J.L. Schneider, MD, PhD, Boston, MA I. Rahman, PhD, ATSF, Rochester, NY

ATS 2023 • Washington, DC